Oxycodone combined with opioid receptor antagonists: efficacy and safety

Bibliography

• Davis MP. Are there cost benefits to fentanyl for breakthrough pain? J Pain Symptom Manage 2012;44:e1-2
   PubMed Web of Science ®Google Scholar
• de Haes H, Koedoot N. Patient centered decision making in palliative cancer treatment: a world of paradoxes. Patient Educ Couns 2003;50:43-9
   PubMed Web of Science ®Google Scholar
• Nickerson RS. Null hypothesis significance testing: a review of an old and continuing controversy. Psychol Methods 2000;5:241-301
   PubMed Web of Science ®Google Scholar
• Walter SD. Choice of effect measure for epidemiological data. J Clin Epidemiol 2000;53:931-9
   PubMed Web of Science ®Google Scholar
• Pakhomov SV, Jacobsen SJ, Chute CG, Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care 2008;14:530-9
   PubMed Web of Science ®Google Scholar
• Fromme EK, Eilers KM, Mori M, How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004;22:3485-90
   PubMed Web of Science ®Google Scholar
• Ravaud P, Tubach F. Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibs. Joint Bone Spine 2005;72:451-5
   PubMed Web of Science ®Google Scholar
• Lundh A, Sismondo S, Lexchin J, Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12:MR000033
   PubMed Web of Science ®Google Scholar
• Poyhia R, Seppala T, Olkkola KT, The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992;33:617-21
   PubMed Web of Science ®Google Scholar
• Backlund M, Lindgren L, Kajimoto Y, Comparison of epidural morphine and oxycodone for pain after abdominal surgery. J Clin Anesth 1997;9:30-5
   PubMed Web of Science ®Google Scholar
• Peckham EM, Traynor JR. Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 2006;316:1195-201
   PubMed Web of Science ®Google Scholar
• Lalovic B, Kharasch E, Hoffer C, Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006;79:461-79
   PubMed Web of Science ®Google Scholar
• Bostrom E, Hammarlund-Udenaes M, Simonsson US. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology 2008;108:495-505
   PubMed Web of Science ®Google Scholar
• Leri F, Burns LH. Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol Biochem Behav 2005;82:252-62
   PubMed Web of Science ®Google Scholar
• Olmstead MC, Burns LH. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology (Berl) 2005;181:576-81
   PubMed Web of Science ®Google Scholar
• Webster LR. Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs 2007;16:1277-83
   PubMed Web of Science ®Google Scholar
• Wang D, Sun X, Sadee W. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 2007;321:544-52
   PubMed Web of Science ®Google Scholar
• Garzon J, Garcia-Espana A, Sanchez-Blazquez P. Opioids binding mu and delta receptors exhibit diverse efficacy in the activation of Gi2 and G(x/z) transducer proteins in mouse periaqueductal gray matter. J Pharmacol Exp Ther 1997;281:549-57
   PubMed Web of Science ®Google Scholar
• Sanchez-Blazquez P, Gomez-Serranillos P, Garzon J. Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull 2001;54:229-35
   PubMed Web of Science ®Google Scholar
• Crain SM, Shen KF. Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Trends Pharmacol Sci 1998;19:358-65
   PubMed Web of Science ®Google Scholar
• Crain SM, Shen KF. Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Neurochem Res 1996;21:1347-51
   PubMed Web of Science ®Google Scholar
• Tsai RY, Tai YH, Tzeng JI, Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein. Neuroscience 2009;164:435-43
   PubMed Web of Science ®Google Scholar
• Wang HY, Frankfurt M, Burns LH. High-affinity naloxone binding to filamin A prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence. PLoS ONE 2008;3:e1554
   PubMed Web of Science ®Google Scholar
• Wang HY, Burns LH. Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. J Neurobiol 2006;66:1302-10
   PubMedGoogle Scholar
• Wang HY, Friedman E, Olmstead MC, Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 2005;135:247-61
   PubMed Web of Science ®Google Scholar
• Barg J, Levy R, Simantov R. Paradoxical and subtype-specific effects of opiate antagonists on the expression of opioid receptors in rat brain cultures. J Neurosci Res 1989;22:322-30
   PubMed Web of Science ®Google Scholar
• Tsai RY, Tai YH, Tzeng JI, Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway. Neuroscience 2009;159:1244-56
   PubMed Web of Science ®Google Scholar
• Mattioli TA, Milne B, Cahill CM. Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats. Mol Pain 2010;6:22
   PubMed Web of Science ®Google Scholar
• Lin SL, Tsai RY, Tai YH, Ultra-low dose naloxone upregulates interleukin-10 expression and suppresses neuroinflammation in morphine-tolerant rat spinal cords. Behav Brain Res 2010;207:30-6
   PubMed Web of Science ®Google Scholar
• Costantino CM, Gomes I, Stockton SD, Opioid receptor heteromers in analgesia. Expert Rev Mol Med 2012;14:e9
   PubMed Web of Science ®Google Scholar
• Davis MP. Evidence from basic research for opioid combinations. Expert Opin Drug Discov 2012;7:165-78
   PubMed Web of Science ®Google Scholar
• Divin MF, Bradbury FA, Carroll FI, Neutral antagonist activity of naltrexone and 6beta-naltrexol in naive and opioid-dependent C6 cells expressing a mu-opioid receptor. Br J Pharmacol 2009;156:1044-53
   PubMed Web of Science ®Google Scholar
• Sadee W, Wang D, Bilsky EJ. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci 2005;76:1427-37
   PubMed Web of Science ®Google Scholar
• Adan RA, Kas MJ. Inverse agonism gains weight. Trends Pharmacol Sci 2003;24:315-21
   PubMed Web of Science ®Google Scholar
• Wang Z, Bilsky EJ, Porreca F, Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 1994;54:PL339-50
   PubMed Web of Science ®Google Scholar
• Cruz SL, Villarreal JE, Volkow ND. Further evidence that naloxone acts as an inverse opiate agonist: implications for drug dependence and withdrawal. Life Sci 1996;58:PL381-9
   PubMed Web of Science ®Google Scholar
• Liu JG, Ruckle MB, Prather PL. Constitutively active mu-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala2,N-MePhe4,Gly-ol5]enkephalin. J Biol Chem 2001;276:37779-86
   PubMed Web of Science ®Google Scholar
• Wang D, Raehal KM, Bilsky EJ, Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 2001;77:1590-600
   PubMed Web of Science ®Google Scholar
• Wang D, Raehal KM, Lin ET, Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther 2004;308:512-20
   PubMed Web of Science ®Google Scholar
• Yancey-Wrona JE, Raymond TJ, Mercer HK, 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice. Life Sci 2009;85:413-20
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
   PubMed Web of Science ®Google Scholar
• Porter SJ, Somogyi AA, White JM. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone. Addict Biol 2002;7:219-25
   PubMed Web of Science ®Google Scholar
• Verebey K, Volavka J, Mule SJ, Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 1976;20:315-28
   PubMed Web of Science ®Google Scholar
• Yancey-Wrona J, Dallaire B, Bilsky E, 6beta-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. Pain Med 2011;12:1727-37
   PubMed Web of Science ®Google Scholar
• Porter SJ, Somogyi AA, White JM. Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. Br J Clin Pharmacol 2000;50:465-71
   PubMed Web of Science ®Google Scholar
• Navani DM, Sirohi S, Madia PA, Yoburn BC. The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice. Pharmacol Biochem Behav 2011;99:671-5
   PubMed Web of Science ®Google Scholar
• Largent-Milnes TM, Guo W, Wang HY, Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J Pain 2008;9:700-13
   PubMed Web of Science ®Google Scholar
• Tompkins DA, Lanier RK, Harrison JA, Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology (Berl) 2010;210:471-80
   PubMed Web of Science ®Google Scholar
• Lowenstein O, Leyendecker P, Hopp M, Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43
   PubMed Web of Science ®Google Scholar
• Sandner-Kiesling A, Leyendecker P, Hopp M, Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 2010;64:763-74
   PubMed Web of Science ®Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Nauck F, Bar-Sela G, A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60
   PubMed Web of Science ®Google Scholar
• Mercadante S. Clarifications on oxycodone-naloxone combination in cancer pain management. Support Care Cancer 2012;20:1351-2
   PubMed Web of Science ®Google Scholar
• Chindalore VL, Craven RA, Yu KP, Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 2005;6:392-9
   PubMed Web of Science ®Google Scholar
• Webster LR, Butera PG, Moran LV, Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006;7:937-46
   PubMed Web of Science ®Google Scholar
• Raffa RB. Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in 'chemo-fog'/'chemo-brain'. J Clin Pharm Ther 2010;35:1-9
   PubMed Web of Science ®Google Scholar
• Butler SF, Black R, Grimes Serrano JM, Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. Pain Med 2010;11:81-91
   PubMed Web of Science ®Google Scholar
• Butler SF, Benoit C, Budman SH, Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006;3:5
   PubMedGoogle Scholar
• Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010;70:1657-75
   PubMed Web of Science ®Google Scholar
• Hays LR. A profile of OxyContin addiction. J Addict Dis 2004;23:1-9
   PubMed Web of Science ®Google Scholar
• McCabe SE, Cranford JA, Boyd CJ, Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007;32:562-75
   PubMed Web of Science ®Google Scholar
• Cone EJ. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend 2006;83(Suppl 1):S31-9
   PubMed Web of Science ®Google Scholar
• Katz NP, Buse DC, Budman SH, Development and preliminary experience with an ease of extractability rating system for prescription opioids. Drug Dev Ind Pharm 2006;32:727-46
   PubMed Web of Science ®Google Scholar
• Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009;10(Suppl 2):S124-33
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012;367:187-9
   PubMed Web of Science ®Google Scholar
• Bannwarth B. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs 2012;72:1713-23
   PubMed Web of Science ®Google Scholar
• Daniels SE, Spivey RJ, Singla S, Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery. Curr Med Res Opin 2011;27:593-603
   PubMed Web of Science ®Google Scholar
• Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs 2010;24:805-10
   PubMed Web of Science ®Google Scholar
• Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain 2010;11:602-11
   PubMed Web of Science ®Google Scholar
• De Schepper HU, Cremonini F, Park MI, Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16:383-94
   PubMed Web of Science ®Google Scholar
• Smith K, Hopp M, Mundin G, Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther 2008;30:2051-68
   PubMed Web of Science ®Google Scholar
• Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23:48-53
   PubMed Web of Science ®Google Scholar
• Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996;10:135-44
   PubMed Web of Science ®Google Scholar
• Sykes NP. Oral naloxone in opioid-associated constipation. Lancet 1991;337:1475
   PubMed Web of Science ®Google Scholar
• Latasch L, Zimmermann M, Eberhardt B, Treatment of morphine-induced constipation with oral naloxone. Anaesthesist 1997;46:191-4
   PubMed Web of Science ®Google Scholar
• Nadstawek J, Leyendecker P, Hopp M, Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract 2008;62:1159-67
   PubMed Web of Science ®Google Scholar
• Simpson K, Leyendecker P, Hopp M, Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24:3503-1
   PubMed Web of Science ®Google Scholar
• Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 1996;12:195-208
   PubMed Web of Science ®Google Scholar
• Mackinnon B, Fraser E, Simpson K, Is it necessary to stop antiplatelet agents before a native renal biopsy? Nephrol Dial Transplant 2008;23:3566-70
   PubMed Web of Science ®Google Scholar
• Lowenstein O, Leyendecker P, Lux EA, Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010;10:12
   PubMedGoogle Scholar
• Schutter U, Grunert S, Meyer C, Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010;26:1377-87
   PubMed Web of Science ®Google Scholar
• Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study. Expert Opin Pharmacother 2012;13:299-311
   PubMed Web of Science ®Google Scholar
• Mercadante S, Ferrera P, Adile C. High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer 2011;19:1471-2
   PubMed Web of Science ®Google Scholar
• Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010;362:865-9
   PubMed Web of Science ®Google Scholar
• Vera-Badillo FE, Shapiro R, Ocana A, Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol 2013;15:564-75
   Google Scholar
• Borenstein M. The case for confidence intervals in controlled clinical trials. Control Clin Trials 1994;15:411-28
   PubMedGoogle Scholar
• Treadwell JR, Uhl S, Tipton K, Assessing equivalence and noninferiority. J Clin Epidemiol 2012;65:1144-9
   PubMed Web of Science ®Google Scholar
• Sykes NP. The pathogenesis of constipation. J Support Oncol 2006;4:213-18
   PubMedGoogle Scholar
• Brock C, Olesen SS, Olesen AE, Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012;72:1847-65
   PubMed Web of Science ®Google Scholar
• Dunlop W, Uhl R, Khan I, Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. J Med Econ 2012;15:564-75
   PubMedGoogle Scholar